文献速递消化系统肿瘤

CDC37基因表达对转移性结直肠癌靶向治疗疗效的预测价值

Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2024-02-10

基于CALGB/SWOG 80405试验和日本回顾性队列分析CDC37表达与转移性结直肠癌靶向治疗疗效的关系。CDC37高表达患者接受贝伐珠单抗为基础治疗及瑞戈非尼的生存获益更优,但接受西妥昔单抗为基础治疗的两组结局相似。分子谱分析显示CDC37高表达肿瘤与血管生成相关通路激活有关。

要点

  • CDC37高表达转移性结直肠癌患者接受贝伐珠单抗为基础治疗的无进展生存更优。
  • CDC37高表达患者接受瑞戈非尼的总生存和无进展生存均更优。
  • CDC37高表达与西妥昔单抗为基础治疗的疗效无显著相关。

核心结论

  • CDC37高表达转移性结直肠癌患者从抗VEGF治疗(包括贝伐珠单抗和瑞戈非尼)中获益更多,但从西妥昔单抗治疗中未获更多获益。
  • 分子谱提示此类肿瘤依赖血管生成相关通路。

研究设计与样本

  • 研究分析了两个独立的转移性结直肠癌队列:CALGB/SWOG 80405试验(接受一线含贝伐珠单抗化疗226例和含西妥昔单抗化疗207例)和日本回顾性队列(接受瑞戈非尼治疗的难治性患者50例),按CDC37表达中位截断值分为高表达和低表达组比较生存结局。
  • 利用商业CLIA认证实验室的标本数据集(CDC37高表达即最高四分位N=5055和低表达即最低四分位N=5055的结直肠癌)分析分子谱特征。

主要发现

  • 在贝伐珠单抗治疗组,CDC37高表达患者较CDC37低表达患者无进展生存显著更优:中位13.3个月 vs 9.6个月,HR 0.59,95%CI 0.44-0.79,p<0.01。
  • 在西妥昔单抗治疗组,CDC37高表达与低表达患者结局相似。
  • 在瑞戈非尼治疗组,CDC37高表达患者较CDC37低表达患者总生存显著更优:中位11.3个月 vs 6.0个月,HR 0.24,95%CI 0.11-0.54,p<0.01;无进展生存显著更优:中位3.5个月 vs 1.9个月,HR 0.51,95%CI 0.28-0.94,p=0.03。
  • 综合分子谱分析显示CDC37高表达结直肠癌与更高的VEGFA、FLT1和KDR表达及活化的缺氧特征相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CDC37 is a key determinant of client kinase recruitment to the HSP90 chaperoning system. We hypothesized that kinase-specific dependency on CDC37 alters the efficacy of targeted therapies for metastatic colorectal cancer (mCRC). MATERIAL AND METHODS: Two independent mCRC cohorts were analyzed to compare the survival outcomes between CDC37-high and CDC37-low patients (stratified by the median cutoff values): the CALGB/SWOG 80405 trial (226 and 207 patients receiving first-line bevacizumab- and cetuximab-containing chemotherapies, respectively) and Japanese retrospective (50 refractory patients receiving regorafenib) cohorts. A dataset of specimens submitted to a commercial CLIA-certified laboratory was utilized to characterize molecular profiles of CDC37-high (top quartile, N = 5055) and CDC37-low (bottom quartile, N = 5055) CRCs. RESULTS: In the bevacizumab-treated group, CDC37-high patients showed significantly better progression-free survival (PFS) (median 13.3 vs 9.6 months, hazard ratio [HR] 0.59, 95% confidence interval [CI] 0.44-0.79, p < 0.01) than CDC37-low patients. In the cetuximab-treated group, CDC37-high and CDC37-low patients had similar outcomes. In the regorafenib-treated group, CDC37-high patients showed significantly better overall survival (median 11.3 vs 6.0 months, HR 0.24, 95% CI 0.11-0.54, p < 0.01) and PFS (median 3.5 vs 1.9 months, HR 0.51, 95% CI 0.28-0.94, p = 0.03). Comprehensive molecular profiling revealed that CDC37-high CRCs were associated with higher VEGFA, FLT1, and KDR expressions and activated hypoxia signature. CONCLUSIONS: CDC37-high mCRC patients derived more benefit from anti-VEGF therapies, including bevacizumab and regorafenib, but not from cetuximab. Molecular profiles suggested that such tumors were dependent on angiogenesis-relating pathways.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Arai H, Yang Y, Baca Y, et al. Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Eur J Cancer. 2024. PMID: 38359495. doi:10.1016/j.ejca.2024.113914

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。